SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

November 13, 2003

Date of Report

(Date of earliest event reported)

 

RITA Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

000-30959		94-3199149
(Commission File Number)		(I.R.S. Employer Identification No.)

 

967 N. Shoreline Blvd.

Mountain View, CA 94043

(Address of principal executive offices, with zip code)

 

(650) 314-3400

(Registrant’s telephone number, including area code)

---

Item 5. Other Events and Required FD Disclosure.

 

On November 13, 2003, RITA Medical Systems, Inc., a Delaware corporation (“RITA”), announced that the Blue Cross and Blue Shield Association Technology Evaluation Center has completed a review of the scientific data supporting radiofrequency ablation and found that the treatment meets the Medical Advisory Panel’s evaluation criteria as therapy for unresectable hepatic malignancies. A copy of RITA’s press release announcing this release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				RITA Medical Systems, Inc.
Date: November 13, 2003				By:		/s/    DONALD STEWART
						Donald Stewart, Chief Financial Officer and Vice President Finance and Administration

---

RITA MEDICAL SYSTEMS, INC.

 

INDEX TO EXHIBITS

 

Exhibit Number		Description
99.1		Press Release of RITA Medical Systems, Inc. dated November 13, 2003.